## Form 4

**United States Securities and Exchange Commission**

Washington, D.C. 20549

**Statement of Changes in Beneficial Ownership**

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

### 1. Name and Address of Reporting Person

Pierce Glenn  
C/O Global Blood Therapeutics, Inc.  
181 Oyster Point Blvd.  
SOUTH SAN FRANCISCO, CA 94080

### 2. Issuer Name and Ticker or Trading Symbol

Global Blood Therapeutics, Inc. [GBT]

### 3. Date of Earliest Transaction

09/10/2020

### 4. If Amendment, Date of Original Filed

09/10/2020

### 5. Relationship of Reporting Person(s) to Issuer

Director  
10% Owner

### 6. Individual or Joint/Group Filing (Check Applicable Line)

Form filed by One Reporting Person

### Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

<table>
<thead>
<tr>
<th>Title of Security</th>
<th>Transaction Date</th>
<th>Deemed Execution Date, if any</th>
<th>Transaction Code</th>
<th>Securities Acquired (A) or Disposed Of (D)</th>
<th>Amount of Securities Beneficially Owned Following Reported Transaction(s)</th>
<th>Price</th>
<th>Ownership Form: Direct (D) or Indirect (I)</th>
<th>Nature of Indirect Beneficial Ownership</th>
</tr>
</thead>
<tbody>
<tr>
<td>Common Stock</td>
<td>09/10/2020</td>
<td></td>
<td></td>
<td>A</td>
<td>15,000</td>
<td>$15.03</td>
<td>D</td>
<td></td>
</tr>
</tbody>
</table>

### Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned

(e.g., puts, calls, warrants, options, convertible securities)

<table>
<thead>
<tr>
<th>Title of Derivative Security</th>
<th>Transaction Date</th>
<th>Deemed Execution Date, if any</th>
<th>Transaction Code</th>
<th>Number of Derivative Securities Acquired (A) or Disposed Of (D)</th>
<th>Date Exercisable and Expiration Date</th>
<th>Title</th>
<th>Amount or Number of Shares</th>
</tr>
</thead>
<tbody>
<tr>
<td>Stock Option (Right to Buy)</td>
<td>09/10/2020</td>
<td></td>
<td></td>
<td>15,000 (1)</td>
<td>02/08/2026 Common Stock</td>
<td>15,000</td>
<td>D</td>
</tr>
</tbody>
</table>

### Explanation of Responses:

1. The shares vested and became exercisable in 36 equal monthly installments, with the first installment on March 8, 2016. This option was subject to accelerated vesting upon a change of control of the Issuer.

### Remarks:

/s/ Tricia Suvari, as Attorney-in-Fact  
09/14/2020

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).


Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.